PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Advances in Therapy0 citationsOpen Access

Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance

ASAkemi SebataViiV Healthcare (Spain)TNTakako NagaoViiV Healthcare (Spain)TMTomoko MatsukawaViiV Healthcare (Spain)

Key Points

  • The aim was to evaluate the long-term safety and effectiveness of dolutegravir and its combinations in Japanese individuals living with HIV.
  • Conducted a 10-year post-marketing surveillance study
  • Analyzed safety and effectiveness profiles of dolutegravir and combinations
  • Monitored for new safety concerns
  • No new safety concerns were identified during the surveillance period
  • Continued support for the established safety profiles of the drugs
  • Reinforcement of their role as key therapeutic options in clinical practice

Abstract

This 10-year post-marketing surveillance confirms the long-term safety and effectiveness of single-agent DTG and DTG/ABC/3TC in Japanese PLHIV. No new safety concerns emerged over the 10-year surveillance period, further supporting their established safety profiles and reinforcing their continued role as key therapeutic options in routine clinical practice.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sebata et al. (2026) studied this question.

synapsesocial.com/papers/69ccb74216edfba7beb89184https://doi.org/10.1007/s12325-026-03544-0
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review2025 · 3 citations
  2. 2‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort2026
  3. 3Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis2024 · 1 citations
  4. 4Clinical Profile and Adverse Effects of Dolutegravir Treatment in HIV-Positive Patients: A Prospective Observational Study2024
  5. 5Efficacy of dolutegravir/lamivudine in adults with <scp>HIV</scp> ‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results2026